ProMedica participates in innovative research into development of non-invasive treatment for BPH

Aug 23 2014

ProMedica is participating in innovative research into the development of a safe, non-invasive treatment for BPH or enlarged prostate. BPH can block the flow of urine out of the bladder and cause bladder, urinary tract or kidney problems. The HistoSonics, Inc. Vortx Rx device is based on histotripsy technology, a non-thermal focused ultrasound therapy that mechanically liquefies targeted tissues.

ProMedica Urologist Timothy Schuster, MD, performed the first Vortx RX experimental treatment to reduce the obstructive symptoms of BPH. It involves using high-intensity sound waves like an acoustic scalpel to break down targeted cells into a liquid that leaves the body during urination.

"Clinical trials are essential to the development of new medical technologies in order to achieve significant advancements in patient care," Dr. Schuster said. "We are pleased to be a part of this pilot study, which is an important first step for histotripsy BPH treatment."

More than 50% of men over the age of 50 and 80% of men 80 or older are affected by BPH. Traditional treatments for BPH include medications and standard and minimally invasive surgeries.

The Vortx RX is an investigational device and is limited by law to investigational use by qualified investigators in the U.S. and Canada.

SOURCE ProMedica